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Table 1
Variables N (%)
Age, yrs (median, range) 33 (18 e 52)
Gender, Male 11 (58%)
Median # of prior therapies (range) 6 (2 e 8)
Prior autoHCT, yes 15 (79%)
Conditioning Intensity, Myeloablative 11 (58%)
Conditioning Regimen
Flu/Bu (AUC 5300, MAC) 9 (47%)
Flu/Bu (AUC 3500, RIC) 3 (16%)
Flu/Cy/TBI 200 1 ( 5%)
Flu/TBI 200 4 (21%)
Pento/Bu 2 (11%)
Disease status at HCT
Complete Remission 5 (26%)
Partial Remission 10 (53%)
Stable Disease 4 (21%)
Donor Type
Matched related 6 (32%)
Matched unrelated 6 (32%)
Mismatched unrelated 6 (32%)
Cord 1 ( 5%)
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outcomes. In this report we examine long-term outcomes of
pts who received initial therapy with RA-SCT followed by
consolidation for HR < CR.
Methods: We performed a retrospective study to assess the
HR rates, incidence of hematologic relapse and progression
(R/POD) and OS of AL pts enrolled at diagnosis on two
consecutive phase II trials using RA-SCT with consolidation
for HR < CR (NCT01527032 and NCT00458822). OS was
calculated from SCT to death or last follow up (f/u). Median
EFS and OS were estimated by the method of Kaplan Meier.
Cumulative incidence function was used to estimate the
incidence of R/POD and death.
Results: Between 2002 and 2011, 83 pts were enrolled and
underwent RA-SCTon these trials. Following RA-SCT, ptswith
HR < CR received consolidation with thalidomide and dexa-
methasone (TD) in the ﬁrst, and bortezomib and dexameth-
asone (BD) in the second trial. 36 pts had cardiac AL (43%) and
all had free light chain (FLC) measurements used to score HR
and R/POD using consensus criteria. The frequency of CR
following SCT was 24% and increased to 48% with post-SCT
consolidation. CR rates increased at 1 yr compared to 3 mos
post-SCT from 21% to 36% with TD and from 28% to 62% with
BD. With a median f/u of 5.1 yrs, the EFS is 4.5 yrs (95% CI: 2.6
to NR) and the OS of all pts has not been reached (Figure 1).16
pts died prior to R/POD and 26 pts have R/POD with
a cumulative incidence of R/POD of 8%, 18%, and 29% at 1, 2
and 3 yrs, respectively. 31% (8/26) of relapsed pts have not
required second-line therapy while among those who have,
78% (14/18) have responded including 44% (8/18) with CR.
Median OS following R/POD was 5 yrs (95% CI: 2.6-5.8).
Conclusions: Half of the AL pts on initial therapy trials
employing RA-SCT and consolidation for HR < CR achieved
CR with 36% of pts on the TD and 62% on the BD consolida-
tion trial in CR at 1 yr post-SCT. At 3 yrs post-SCT the
cumulative incidence of R/POD was 29% and 1/3 of relapsed
pts did not require therapy, likely due to the very sensitive
FLC assay that detects low level R/POD in the absence of
organ progression. Almost 80% of pts requiring second-line
therapy responded, over half with CR, and median OS after
relapse was 5 yrs. These results indicate that initial therapy
with RA-SCT and consolidation is effective for patients with
AL in the era of novel agents, and even relapsing pts have
excellent outcomes. With over 5 ys of f/u, median OS has not
been reached.
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Prognosis is poor for patients (pts) with refractory HL or
for those who relapse following autologous HCT (autoHCT).
Current salvage options aside from alloHCT remain palliative
but the role, timing and utility of alloHCT is not clear. We
report outcomes of 19 consecutive pts (Table 1) with
relapsed/refractory HL receiving alloHCT between 2005 and
2011 at Mofﬁtt Cancer Center. Data were obtained from the
BMT database and supplemented with chart review. Disease
responses are based on Cheson criteria (JCO 2007) and
chemotherapy sensitivity is deﬁned as PR or better at time of
alloHCT. Median follow-up for survivors is 44 months
(14e56). Treatment-relatedmortality (TRM) at day 100 and 1
yr are 27% (95% CI: 10-50) and 44% (95% CI: 23-67). The 1 yr
relapse rate was 32% (95% CI: 13e54). Grade 2 e 4 acute
GVHD by day 100 occurred in 82% (95% CI: 54e98); chronic
GVHD of any severity at 1 yr was 57% (95% CI: 25e86). Overall
survival (OS) and progression-free survival (PFS) at 1 yr are
47% (95% CI: 26-68) and 26% (95% CI: 10-48), respectively.
There were no differences in OS or PFS comparing myeloa-
blative (MAC) to reduced intensity (RIC) conditioning [OS:
MAC 55% (95% CI: 26e82) vs RIC 38% (95% CI: 10e71), P¼ .39;
PFS: MAC 27% (95% CI: 6e56) vs RIC 25% (95% CI: 3e58) P ¼
.78]. Relapse and TRM did not differ by conditioning inten-
sity. Disease status (CR vs PR/Stable disease) did not impact
OS, PFS, relapse or TRM. Pts receiving a mismatched unre-
lated donor (mMUD), including cord, had higher day 100
TRM compared to pts receiving a fully matched donor
[mMUD: 57% (95% CI: 22e88) vs matched: 9% (95%
CI:0e32)]. Three pts, including 1 receiving a mMUD, received
3 lines of chemotherapy including autoHCT preceding
allografting. In these pts, no TRM occurred compared to pts
with >3 lines of prior therapy having TRM of 53% (95% CI:
29e77). However, the improvement in 1 yr OS and PFS was
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(95% CI: 14e100); >3 lines¼OS 44% (95% CI: 21e68), P ¼ .08;
PFS 19% (95% CI: 4e41), P ¼ .06] likely due to limited pts. We
conclude that alloHCT for relapsed/refractory HL can induce
durable remissions; however, outcomes are impaired due to
early TRM in heavily pretreated pts and those receiving
mMUD/cord. While our data are limited by small numbers,
they suggest that pts should be referred for discussion of
alloHCT earlier to mitigate likely adverse toxicity from
repeated therapies.
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Cytomegalovirus (CMV) infection is one of signiﬁcant
factors contribute to morbidity and mortality in recipients
of allogeneic hematopoietic stem cell transplantation (allo-
HSCT). Prevention and treatment of active CMV infection
based on monitoring CMV-pp65 antigenemia test or CMV-
DNA PCR assay have been done in this ﬁeld. The patients of
adult T-cell leukemia/lymphoma (ATLL) are usually in
immunocompromised status and some reports suggested
that CMV reactivation occur with higher frequency in ATLL
patients than other hematological malignancy during their
chemotherapy periods. However, to our knowledge, there
were few reports about relationships between CMV-pp65
antigenemia and recipients of allo-HSCT in ATLL. Our
institute is located in endemic areas of ATLL. Here we
analyzed disease speciﬁc impact for incidence of CMV-pp65
antigenemia in our institute. There were 97 patients had
been consecutively undergone allo-HSCT from November
2006 to May 2012 in Imamura Bun-in Hospital, Kagoshima,
Japan. We excluded 12 patients from our study because of
their early deaths before 30 days after HSCT or neutrophil
recovery. The rest of 85 patients (52 males, 33 females)
were analyzed. We statistically analyzed whether ATLL has
disease speciﬁc signiﬁcance with incidence of CMV-pp65
antigenemia after allo-HSCT. Median age was 52 yrs (19-
69). Thirty seven ATLL patients and 48 non-ATLL patients
were included respectively. There were 19 patients had
been transplanted from sibling donors (7 BM, 12 PB) and 66
unrelated donors (56 BM, 10 CB), respectively. Sixty four
patients received MAC regimen and 21 RIC before allo-
HSCT, respectively. There were 68 patients (27 ATLL, 41
non-ATLL) who could be identiﬁed prevalence of CMV-IgG
antibody before transplantation. There were no statistically
signiﬁcant differences between age >¼ 50 and < 50
patients about CMV-IgG antibody prevalence rate in ATLL
patients. On the other hand it was shown that signiﬁcantly
higher prevalence of CMV-IgG antibody in young patients
than in elder patients in non-ATLL (P ¼ 0,002). There were
63 (34 ATLL, 29 non-ATLL) out of 85 patients who were
developed CMV-pp65 antigenemia, and 7 CMV related
diseases (6 colitis, 1 pneumonia). Cumulative incidence of
CMV-pp65 antigenemia were signiﬁcantly higher in ATLL
(91.9% vs 60.4%, P < .001) and age >¼ 50 yrs patients (89.6%
vs 54.1%, P ¼ .002), respectively. Almost two-thirds of
patients who were developed CMV-pp65 antigenemia had
been administered iv steroid within 10 days before onset. In
multivariate analysis of 63 patients who were identiﬁed ashaving prevalence of CMV-IgG antibody before trans-
plantation, ATLL (HR: 2.625, P ¼ .008), RIC (HR: 2.532, P ¼
.014) were signiﬁcant factors for incidence of CMV-pp65
antigenemia, respectively. In conclusion, ATLL could be one
of independent factors impacting for incidence of CMV-
pp65 antigenemia.249
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Background: Gruppo Italian Trapianto di Midollo Osseo
(GITMO) recently proposed a deﬁnition for proven “poor
mobilizer” (PM) and criteria for predicted PM (pPM) based
on G chemotherapy basedmobilization strategy. Data from
use of combination of G + P for mobilization (Mob) was not
utilized in this proposal. We evaluate these criteria in our pts
with lymphoma to identify speciﬁc prognostic factors.
Patients and Methods: Data from 122 consecutive
lymphoma pts, undergoing Stem Cell Mobilization (SCM)
using G 10 mg/kg SC given at 6.00am on D 1-4 + P 0.24 mg/kg
SC given once daily in an out-patient setting starting D 4, at
our institution from 2009-2012, were collected. PM and pPM
pts were identiﬁed based on the GITMO criteria. PM were
deﬁned as pts who collected< 2.0 x 106 CD34+ cells/kg in 3
apheresis. pPM pts were identiﬁed based on proposed
criteria of 1 major or at least 2 minor criteria. Demographics,
comorbidities, disease status and prior therapies were
identiﬁed and collected.
Results: 122 pts with lymphoma (average age 52.45 yrs,
range: 19-79 yrs) were identiﬁed and analyzed as a retro-
spective cohort. 70 (57%) pts were male and 52 (43%) pts
female. 43 (35.2%) pts had2 comorbidities. 88 (72%) pts had
B-NHL, 11 (9%) T-NHL and 23 (19%) HD. Based on the GITMO
deﬁnitions we identiﬁed 19 (15.6%) pts [avg age 57.84 yrs;
range: 40-72 yrs] were proven PM and 51 (41.8%) pts [avg age
55.9 yrs; range: 27-79 yrs] predicted PM. 3 PM (15.8%) pts
and 10 pPM (19.6%) pts had prior full courses of therapies
that could adversely affect SCM. 3 PM pts and 19 pPM pts
were> 65 yrs. 10 pPM (19.6%) pts had one major and 41 pPM
(80.4%) pts had atleast 2 minor criteria favoring poor mobi-
lization. In pPM pts the median total CD34+ cell yield was
4.46 x106 cells/kg in a median of 2 days (range: 1-4 days). 17
pPM (33.3%) pts achieved the minimumCD34+ cell yield of 
2 x106 cells/kg within 1 pheresis day. Advanced disease,
refractory disease, extensive BM involvement or cellularity
<30% and age > 65 did impact the SCM or predict poor
mobilization in either group. No speciﬁc predictors were
identiﬁed in PM pts.
Conclusion: We conclude that the use of Gruppo Italian
Trapianto di Midollo Osseo (GITMO) criteria for prior iden-
tiﬁcation of proven or predicted poor mobilizers although
does help to identify potential poor mobilizers in patients
with lymphoma, it does not predict the stem cell collection.
However it does support the theory that this group of
patients would beneﬁt from use of alternative mobilization
agents as Plerixafor.
